Background: Levosimendan, a calcium sensitizer, enhances the myocardial function by
generating more energy-efficient myocardial contractility than that achieved through …

Levosimendan increasingly has been used to treat heart failure and cardiac dysfunction in
pediatric patients. Currently, there is only limited evidence that this drug positively affects …

Background Low cardiac output syndrome remains a serious complication, and accounts for
substantial morbidity and mortality in the postoperative course of paediatric patients …

BACKGROUND Low cardiac output syndrome (LCOS) after congenital cardiac surgery has
an incidence of up to 25%. Preventing and treating LCOS is of pivotal importance as LCOS …

Background The role of prophylactic levosimendan in patients undergoing cardiac surgery is
controversial. Methods We performed a computerized search of Medline, Embase, and …

Background There has been conflicting evidence concerning the effect of levosimendan on
clinical outcomes in patients undergoing cardiac surgery. Therefore, we performed a …

Introduction Low cardiac output syndrome (LCOS) is a significant cause of morbidity and the
leading cause of mortality after pediatric cardiac surgery. Levosimendan has been shown …

Background The administration of levosimendan prophylactically to patients undergoing
cardiac surgery remains a controversial practice, and few studies have specifically assessed …

Objective: Low cardiac output syndrome commonly complicates the postoperative course
after open-heart surgery in children. To prevent low cardiac output syndrome, prophylactic …

Background: Levosimendan is a calcium sensitizer drug causing increased contractility in
the myocardium and vasodilation in the vascular system. It is mainly used for the therapy of …